Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Janakiraman Subramanian, Jamie Cavenagh, Bhardwaj Desai & Ira Jacobs. (2017) Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape. Cancer Management and Research 9, pages 131-140.
Read now
Read now
András Inotai, Christiaan P.J Prins, Marcell Csanádi, Dinko Vitezic, Catalin Codreanu & Zoltán Kaló. (2017) Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opinion on Biological Therapy 17:8, pages 915-926.
Read now
Read now
Ira Jacobs, Ena Singh, K Lea Sewell, Ahmad AL-Sabbagh & Lesley G Shane. (2016) Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Preference and Adherence 10, pages 937-948.
Read now
Read now
Antonio da Silva, Ulrich Kronthaler, Vera Koppenburg, Martin Fink, Ines Meyer, Anastassia Papandrikopoulou, Matthias Hofmann, Thomas Stangler & Jan Visser. (2014) Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leukemia & Lymphoma 55:7, pages 1609-1617.
Read now
Read now
Md Yuzaiful Md Yusof, Edward MJ Vital & Paul Emery. (2013) B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. Expert Review of Clinical Immunology 9:8, pages 761-772.
Read now
Read now
Articles from other publishers (29)
Stefka Stoyanova, Emanuil Yordanov, Emil Hristov, Iva Parvova, Hristo Tzachev & Valentina Petkova. (2021) Availability, affordability and drug utilization of biosimilar medicinal products, containing monoclonal antibodies in Bulgaria. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 18:1, pages 42-50.
Crossref
Crossref
Andrew R Melville, Md Yuzaiful Md Yusof, John Fitton, Leticia Garcia-Montoya, Lynda Bailey, Shouvik Dass, Paul Emery, Maya H Buch & Benazir Saleem. (2021) Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. Rheumatology 60:8, pages 3679-3688.
Crossref
Crossref
Luis Pérez Díaz, Susana Millán, Nuran Chaban, Ana del Campo & Eduardo Spitzer. (2021) Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncology 17:19, pages 2529-2544.
Crossref
Crossref
Lukas Uhrik, Lenka Hernychova, Petr Muller, Umesh Kalathiya, Malgorzata M. Lisowska, Mikolaj KocikowskiMaciej ParysJakub Faktor, Marta Nekulova, Chris NortcliffePavlina Zatloukalova, Barbara Ruetgen, Robin Fahraeus, Kathryn L. BallDavid J. ArgyleBorivoj Vojtesek & Ted R. Hupp. (2021) Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody. Biochemical Journal 478:1, pages 99-120.
Crossref
Crossref
Morton Scheinberg & Valderilio Azevedo. (2019) The future landscape of biosimilars in rheumatology: Where we are where we are going. Autoimmunity Reviews 18:2, pages 203-208.
Crossref
Crossref
Kristine Oleinika, Claudia Mauri & Alan D. Salama. (2018) Effector and regulatory B cells in immune-mediated kidney disease. Nature Reviews Nephrology 15:1, pages 11-26.
Crossref
Crossref
Ciara L. Freeman & Laurie Sehn. (2018) Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. Current Oncology Reports 20:12.
Crossref
Crossref
Fadi Farhat, Alfredo Torres, Wungki Park, Gilberto de Lima Lopes, Raja Mudad, Chukwuemeka Ikpeazu & Simon Abi Aad. (2018) The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review. The Oncologist 23:3, pages 346-352.
Crossref
Crossref
Divyanshu DubeyThomas ForsthuberEoin P. FlanaganSean J. PittockOlaf Stüve. (2017) B-cell–targeted therapies in relapsing forms of MS. Neurology Neuroimmunology & Neuroinflammation 4:6.
Crossref
Crossref
Dae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, Slawomir Jeka, Francisco Fidencio Cons Molina, Pawel Hrycaj, Piotr Wiland, Eun Young Lee, Francisco G. Medina-Rodriguez, Pavel Shesternya, Sebastiao Radominski, Marina Stanislav, Volodymyr Kovalenko, Dong Hyuk Sheen, Leysan Myasoutova, Mie Jin Lim, Jung-Yoon Choe, Sang Joon Lee, Sung Young Lee, Sung Hwan Kim & Won Park. (2017) Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial. BioDrugs 31:4, pages 357-367.
Crossref
Crossref
Ira Jacobs, Reginald Ewesuedo, Sadiq Lula & Charles Zacharchuk. (2017) Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence. BioDrugs 31:1, pages 1-36.
Crossref
Crossref
João Eurico Fonseca & João Gonçalves. 2016. Biosimilars of Monoclonal Antibodies. Biosimilars of Monoclonal Antibodies
479
503
.
Regis Sodoyer. 2016. Biosimilars of Monoclonal Antibodies. Biosimilars of Monoclonal Antibodies
1
62
.
Ira Jacobs, Danielle Petersel, Lesley G. Shane, Chee-Keng Ng, Carol Kirchhoff, Gregory Finch & Sadiq Lula. (2016) Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence. BioDrugs 30:6, pages 489-523.
Crossref
Crossref
Hector A. Cuello, Valeria I. Segatori, Marina Alberto, Analía Pesce, Daniel F. Alonso & Mariano R. Gabri. (2016) Comparability of Antibody-Mediated Cell Killing Activity Between a Proposed Biosimilar RTXM83 and the Originator Rituximab. BioDrugs 30:3, pages 225-231.
Crossref
Crossref
Zichuan Zhang, Ronel Perrault, Yun Zhao & Julia Ding. (2016) SpeB proteolysis with imaged capillary isoelectric focusing for the characterization of domain-specific charge heterogeneities of reference and biosimilar Rituximab. Journal of Chromatography B 1020, pages 148-157.
Crossref
Crossref
Majed Khraishi, David Stead, Milan Lukas, Florian Scotte & Holger Schmid. (2016) Biosimilars: A Multidisciplinary Perspective. Clinical Therapeutics 38:5, pages 1238-1249.
Crossref
Crossref
Eduardo Mysler, Carlos Pineda, Takahiko Horiuchi, Ena Singh, Ehab Mahgoub, Javier Coindreau & Ira Jacobs. (2016) Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatology International 36:5, pages 613-625.
Crossref
Crossref
Saurabh Jain, Luca Aresu, Stefano Comazzi, Jianguo Shi, Erin Worrall, John Clayton, William Humphries, Sandra Hemmington, Paul Davis, Euan Murray, Asmare A. Limeneh, Kathryn Ball, Eva Ruckova, Petr Muller, Borek Vojtesek, Robin Fahraeus, David Argyle & Ted R. Hupp. (2016) The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLOS ONE 11:2, pages e0148366.
Crossref
Crossref
Sarfaraz Niazi. 2015. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
83
122
.
Sarfaraz Niazi. 2015. Biosimilars and Interchangeable Biologics. Biosimilars and Interchangeable Biologics
1
22
.
Pere Gascon. (2015) The evolving role of biosimilars in haematology–oncology: a practical perspective. Therapeutic Advances in Hematology 6:6, pages 267-281.
Crossref
Crossref
Thomas Dörner & Jonathan Kay. (2015) Biosimilars in rheumatology: current perspectives and lessons learnt. Nature Reviews Rheumatology 11:12, pages 713-724.
Crossref
Crossref
Md Yuzaiful Md Yusof, Edward M. Vital & Maya H. Buch. (2015) B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Current Rheumatology Reports 17:10.
Crossref
Crossref
Kuttipurath Kandi Roshique & Vinod Ravindran. (2015) Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis. Clinical Rheumatology 34:7, pages 1289-1292.
Crossref
Crossref
Ed Vital. 2015. Atlas of Rheumatoid Arthritis. Atlas of Rheumatoid Arthritis
233
249
.
Md Yuzaiful Md Yusof, Edward M Vital & Paul Emery. (2014) Biologics in systemic lupus erythematosus: current options and future perspectives. British Journal of Hospital Medicine 75:8, pages 440-447.
Crossref
Crossref
William Baer II, Archana Maini & Ira Jacobs. (2014) Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Pharmaceuticals 7:5, pages 530-544.
Crossref
Crossref
Daniel J Martinusen, Clifford Lo, Judith G Marin, Nicole W Tsao & Marianna Leung. (2014) Potential Impact of Subsequent Entry Biologics in Nephrology Practice in Canada. Canadian Journal of Kidney Health and Disease 1, pages 32.
Crossref
Crossref